Direct antiviral agents (DAA) demonstrated high efficacy among HCV-infected patients in registered trials. Nevertheless, the impact of these therapies on liver stiffness measurement (LSM) and liver functionality in ‘real-life’ is not well-known. The aim of the present study was to evaluate the sustained virological response (SVR) impact on LSM and clinical parameters of DAA-therapy on a real-life population of HCV patients with F3/F4 fibrosis.
Methods
A total of 749 HCV genotype 1–4 patients with F3/F4 hepatitis undergoing antiviral therapy were consecutively enrolled in four centres of hepatology in Italy. Clinical, biochemical and imaging data were collected at the baseline (T0), at the end of treatment (EoT) and after 12 weeks (SVR12).
Results
Out of 749 patients, 69.7% were F4 and 30.3% were F3. SVR12 was reached in 97.5%. LSM significantly decreased from T0 to EoT (P<0.001), whereas, it did not from EoT to SVR12 (P= not significant). Moreover, in F4 no significant differences were found in Child and MELD between T0, EoT and SVR12 (P= not significant). At the univariate analysis of clinical and liver parameters, baseline high glucose (P<0.005), type 2 diabetes (P<0.001), low alanine aminotransferase (ALT; P<0.001), low platelets (P<0.005), and the presence of esophageal varices (EV; P<0.001) were found to be associated with a lack of a significant EoT LSM improvement. At multiple regression, ALT (P<0.05), diabetes (P<0.005) and EV (P<0.05) were inversely associated with significant LSM reduction.
Conclusions
Virological response to DAA is associated with fibrosis regression and recovery of liver functionality and this can be detected as early as EoT. HCV eradication is associated with a rapid and significant clinical improvement that lasts over time and seems to be negatively influenced by diabetes and EV.
References
1.
HajarizadehB., GrebelyJ., DoreG.J.Epidemiology and natural history of HCV infection.Nat Rev Gastroenterol Hepatol2013; 10: 553–562.
2.
AsselahT., BoyerN., SaadounD., Martinot-PeignouxM., MarcellinP.Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Liver Int2016; 36Suppl 2: 47–57.
3.
FosterG.R., IrvingW.L., CheungM.C.Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol2016; 64: 1224–1231.
4.
BrunoS., StroffoliniT., ColomboM.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.Hepatology2007; 45: 579–587.
5.
van der MeerA.J., FeldJ.J., HoferH.Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol2017; 66: 485–493.
6.
BrunoS., Di MarcoV., IavaroneM.Improved survival of patients with hepatocellular carcinoma and compensated HCV-related cirrhosis who attained SVR.Liver Int2017; 37: 1526–1534.
7.
PoynardT., McHutchisonJ., MannsM.Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.Gastroenterology2002; 122: 1303–1313.
8.
van der MeerA.J., MaanR., VeldtB.J.Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.J Gastroenterol Hepatol2016; 31: 1168–1176.
9.
FontanaR.J., BrownR.S.Jr., Moreno-ZamoraA.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Liver Transpl2016; 22: 446–458.
10.
PoordadF., SchiffE.R., VierlingJ.M.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.Hepatology2016; 63: 1493–1505.
11.
RockeyD.C., CaldwellS.H., GoodmanZ.D., NelsonR.C., SmithA.D.American Association for the Study of Liver Diseases. Liver biopsy.Hepatology2009; 49: 1017–1044.
12.
SterlingR.K., LissenE., ClumeckN.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology2006; 43: 1317–1325.
13.
WaiC.T., GreensonJ.K., FontanaR.J.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Hepatology2003; 38: 518–526.
14.
ZiolM., Handra-LucaA., KettanehA.Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.Hepatology2005; 41: 48–54.
15.
CasteraL., FornsX., AlbertiA.Non-invasive evaluation of liver fibrosis using transient elastography.J Hepatol2008; 48: 835–847.
16.
Friedrich-RustM., OngM.F., MartensS.Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.Gastroenterology2008; 134: 960–974.
17.
TalwalkarJ.A., KurtzD.M., SchoenleberS.J., WestC.P., MontoriV.M.Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis.Clin Gastroenterol Hepatol2007; 5: 1214–1220.
18.
StebbingJ., FaroukL., PanosG.A meta-analysis of transient elastography for the detection of hepatic fibrosis.J Clin Gastroenterol2010; 44: 214–219.
19.
TanejaS., TohraS., DusejaA., DhimanR.K., ChawlaY.K.Noninvasive assessment of liver fibrosis by transient elastography and FIB4/APRI for prediction of treatment response in chronic hepatitis C-an experience from a tertiary care hospital.J Clin Exp Hepatol2016; 6: 282–290.
20.
BerzigottiA.Non-invasive evaluation of portal hypertension using ultrasound elastography.J Hepatol2017; 67: 399–411.
21.
CocoB., OliveriF., MainaA.M.Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.J Viral Hepat2007; 14: 360–369.
SagirA., ErhardtA., SchmittM., HaussingerD.Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage.Hepatology2008; 47: 592–595.
24.
AISF. Indication document of the Italian Association for the Study of the Liver for the Rational Use of Second Generation Direct Antivirals Agents in the Categories of Chronic Hepatitis C Accepted for Reimbursement in Italy. (Accessed 23 November 2017.) Available from http://www.webaisf.org/media/39700/documento_hcv_241017.pdf.
25.
European Association for the Study of the Liver.EASL Recommendations on Treatment of Hepatitis C 2016.J Hepatol2017; 66: 153–194.
26.
European Association for Study of Liver.Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.J Hepatol2015; 63: 237–264.
27.
Garcia-TsaoG., SanyalA.J., GraceN.D., CareyW.Practice Guidelines Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.Hepatology2007; 46: 922–938.
28.
ContiF., BuonfiglioliF., ScuteriA.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.J Hepatol2016; 65: 727–733.
29.
ReigM., MarinoZ., PerelloC.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.J Hepatol2016; 65: 719–726.
30.
BruixJ., ShermanM.American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.Hepatology2011; 53: 1020–1022.
31.
European Association For The Study Of The Liver.European Organisation For Research and Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012; 56: 908–943.
32.
SoveriniV., PersicoM., BugianesiE.HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas.Acta Diabetol2011; 48: 337–343.
33.
HuiJ.M., SudA., FarrellG.C.Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression.Gastroenterology2003; 125: 1695–1704.
34.
HuangC.F., DaiC.Y., YehM.L.Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.J Hepatol2015; 62: 512–518.
35.
FartouxL., Poujol-RobertA., GuechotJ., WendumD., PouponR., SerfatyL.Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.Gut2005; 54: 1003–1008.
36.
BallestriS., NascimbeniF., RomagnoliD., BaldelliE., TargherG., LonardoA.Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection–liver: The “Musketeer” in the Spotlight.Int J Mol Sci2016; 17: 355.
37.
ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts.J Hepatol2016; 65: 734–740.
38.
BielenR., MorenoC., Van VlierbergheH.The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience.J Viral Hepat2017; 24: 976–981.
39.
CheungM.C., WalkerA.J., HudsonB.E.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol2016; 65: 741–747.
40.
KobayashiM., SuzukiF., FujiyamaS.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.J Med Virol2017; 89: 476–483.
